China Biotech Services expects H1 net profit of at least HK$15 million, swings from loss

• China Biotech Services expects net profit of at least HK$15 million for the six months ended June 30, 2026.
• That compares with a net loss of about HK$37 million a year earlier.
• Forecast driven by a non-cash, unrealized fair value gain on convertible bonds of HK$77 million to HK$87 million.
• Higher finance costs of about HK$9 million tied to USD 35 million convertible bonds issued in February 2026.
• Prior-year results included a non-recurring insurance compensation income of about HK$14 million that did not repeat.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260812-12281989), on August 12, 2026, and is solely responsible for the information contained therein.